Majororthopedicsurgery isknowntobeassociated withp otentiallys erious arterialand venous vascularcomplications,althoughuncertainty exists about currenteventrates.Using electronicdatabasesand investigatorcontact,wei dentified randomizedand cohort studiesr eporting overallm ortality and fatal vascularevents.Wherepossible,studiesreporting high autopsy rates(>60%) wereexamined.Pooledincidenceswerecalculated from eligible studies.For Autopsy studies :Pooledoverallmortality and fatalpulmonary embolismforpatients undergoing electivehip and knee replacementwithout prophylaxiscouldnotbe calculated,while withprophylaxistheywere0.44% (95% confidenceinterval0.02 to0.87%) and 0.43%(0.01to0.85%). Forpatients undergoing hip fracturesurgery,the corresponding rates without prophylaxisw ere15.9% (14.5 to17.3%) and 1.9% (1.4 to2.4%).Withprophylaxis,mortality and fatalpulmonary embolKeywords Orthopedicsurgery,prophylaxis,fatalvascularoutcomes ismrateswere8.5% (7.3to9.7%) and 1.0%(0.6to1.5%). Among Cohort studies :Pooledoverallmortality and fatalpulmonary embolismf orpatients undergoing electiveh ip and knee replacementw ithout prophylaxisw ere0.93%( 0.57t o1 .29%) and 0.36%(0.14 to0.59%). Forpatients receiving prophylaxis(7to 14 days),mortality and fatalp ulmonary embolismwere0.57% (0.51 to0.62%) and 0.18% (0.14 to0.21%). Patients undergoing hip fracturesurgery receiving prophylaxishadmortality and fatal pulmonary embolismratesof 3.2%(2.8 to3.6%) and 0.30%(0to 0.61%).Vascularevents contributed towardsapproximately50% of all deathswithsimilarproportionsduetoischemicheart disease,cardiac failureand pulmonary embolism. Inconclusion,althoughprophylaxisresults in areductioninoverallmortality and fatalp ulmonary embolism,vascularevents continuetobea common causeofmortality.
Introduction
Currentlymorethantwomillion people in the United Statesand Europe undergo majororthopedicsurgery eachyear.Annual proceduraln umbersarei ncreasing;a25-35% increasei nthe numberof electiveproceduresispredicted overthe next 30 years (1,2),while the numberof patients undergoing hip fracturesurgery isexpected totriple by2030-2050.
Majororthopedicsurgery isassociated withsystemica ctivation of coagulation (3, 4) withpotentiallyserious,and attimes fatal,vascularcomplications,suchasmyocardiali nfarction, strokeand venous thromboembolism (5) (6) (7) (8) . Among the predominantlyelderlypopulation undergoing theseprocedures,coexisting cardiac, pulmonary,cerebralandrenaldiseaseareoften presentthus increasing the likelihood of post-operativevascular events.
Ofthe post-operativevascularevents,venous thromboembolismisanimportantandwellrecognizedcauseofmortality, morbidity and hospitalreadmission (9) . Topreventreadmission forsymptomaticthromboembolicevents,fatalitiesand probable deep venous insufficiency,thromboprophylaxisisr ecommendedinall patientgroups (9) . Pooled datademonstratesignificantreductionsin the incidenceoffatalpulmonary embolismand overall mortality withtheshort termuseo fh eparin based prophylaxis (10) . Itisplausible thatthe mortality reduction seen withthe useofthromboprophylaxismaybeduetoprevention of overall vascularevents.Although arterialandvenous thrombosisarecommonlythoughttobetwodifferentdisorders, recentevidencesuggests ancommon pathogenicprocess betweenidiopathicvenousthromboembolismandatherosclerosis (11) . Furthermore,among patients undergoing majororthopedic surgery itisthoughtthatatheroscleroticplaquesmaybethe site forarterialthrombus formationand thatbone surgery triggers arterialevents in addition tovenous events (3, 4) ,the latterhaving beenthe focusof clinicalattention formanyyears.Dataconcerning arterialvascularcomplicationsfollowingmajororthopedic surgery and theirsequelaearehoweverscarce,theseevents have previouslynotbeenattributed tothe surgicaltrauma perse and haveachieved little preventativeattention compared tovenous events.
Inordertoprovide estimatesconcerning mortality,fatalvascularoutcomes(including venous and arterialevents)inpatients undergoing majororthopedicsurgery,weundertook areviewof autopsy data,unpublishedsourced ataa nd clinicalo utcome studies.
Methods
Weconducted aliteraturereviewappertaining tothe currentevidenceconcerning fatalvascularoutcomesfollowingm ajororthopedicsurgery.Toidentifyrelevantpublishedstudieson this topic, electronicdatabases(MEDLINE, EMBASE)were searched using the followingterms: autopsy,deepveinthrombosis,hipfracturesurgery,myocardialinfarction,pulmonary embolism,stroke,thrombosis,totalknee replacement,totalhip replacement,a nd venous thromboembolism. Bibliographiesof journalarticlesw erehand-searched tolocateadditionalstudies and abstracts from majorinternationalmeetingswerereviewed. Relevancewasassessed using ahierarchicalapproachbased on title,a bstract,a nd publishedo ru npublishedm anuscripts.Severalofthe authors alsoprovided unpublishedsourcedataregarding clinicaloutcomes.Wherepossible studieswithhigh autopsy rates(>60%) wereidentified.
Statisticalanalyses
Identifiedstudieswereinitiallyseparated intothe type of surgicali ntervention,b eing electiveh ip orkneereplacementor emergencyhip fracturesurgery.Identifiedstudiesw erefurther divided intowhethertheywererandomized orcohort (prospectiveorretrospectiveobservational) in design.Thereafterstudies werepooled toobtain quantitativeestimatesof the risksof mortality and fatalvascularevents according towhetherprophylaxiswasgiven ornot.Nodifferentiation wasmade according tothe type of prophylacticagent(heparin,low-molecularweightheparin,warfarin) given. Wherenodifferencewasseen in outcomes betweencohort studiesand randomized trials,datawaspooled. Pooled incidenceswereestimated bycombining the dataof each trialweighted firstlybythe inverseofthe variance (12) and secondlybythe inverseofthe sample size. Sincethe results werethe same,onlythe first method of pooling wasused. When aratewas equaltozero,the numberof events equalto0wascorrected by 0.25toallowforthe computation of the variance.
Results

Overall mortality and fatalpulmonary embolism
Autopsy studies Mortality and fatalpulmonary embolisminpatients undergoing electivejointreplacementandemergencyhip fracturesurgery in studiesw heregreaterthan60%ofpatients enrolledunderwent autopsy areshowninTables1and 2.Allstudieswhereprophylaxiswasgiven wererandomized,whereasthoseevaluating outcomesin patients notreceiving prophylaxisw ereobservational in design.Onlyone studybySheppeardetal. (13) * Includesobservationaland randomized studieswithgreaterthan60% of patients undergoing autopsy. †Includespatients receivinglow-molecularweightheparin,unfractionated heparin and warfarin. ‡Prophylactic anticoagulationwasused in approximately20%ofpatients. §Based on overall populationof42,278patients undergoing orthopedicsurgery. ¶Based on fataland contributory pulmonary embolismdetected at autopsy,afurthertwofatalpulmonary embolismwereclinicallysuspectedascauseofdeath. **Based on overall studypopulationof23,078 patients undergoing all formsof surgery. † †Acontinuity correctionwas used (36) . I/P=In-patient; NA =Notapplicable;PE =Pulmonary embolism;R=Randomized;TKR =Totalkneereplacement; THR=Totalhip replacement.
pooled mortality ratewas0.44% (95% confidenceinterval(CI) 0.02 to0.87%) withthe vast majority of deaths(85%,95% CI 60.8 to100%) being duetofatalpulmonary embolism. Among patients undergoing hip fracturesurgery,overall mortality was higher,the pooledratebeing 15.9% (95% CI 14.5 to17.3%) for patients notr eceiving prophylaxisand 8.5% (95% CI 7.3t o 9.7%) forthosereceiving prophylaxis.The pooled incidenceof fatalpulmonary embolismwas1.9% (95% CI 1.4 to2.4%) for patients notr eceiving prophylaxisand 1.0%( 95% CI 0.6 to1 .5%) fort hosereceiving prophylaxis.The contribution of fatalp ulmonary embolismtoo verall mortality wass imilar (13t o1 4%),irrespectiveo fwhetherprophylaxisw asgiven or not.
Cohort studies
Tables3and 4showoverall mortality and fatalpulmonary embolisme vents in cohort studies(electiveande mergencyprocedures),wherethecauseofdeathwasnotroutinelyassessed by autopsy.Inelectivehip orkneereplacementstudies,the pooled overall mortality forpatients notr eceiving prophylaxisw as 0.93%( 95% CI 0.57t o1 .29%) and 0.57%( 95% CI 0.51 to 0.62%) forthosereceiving prophylaxis.The pooled incidenceof fatalpulmonary embolismforpatients notreceiving prophylaxiswas0.36%(95% CI 0.14 to0.59%) and 0.18% (95% CI 0.14 to0.21%) forthosereceiving prophylaxis.Fatalpulmonary embolismthereforecontributed towards33to44% of overall morality.The duration of followupvaried between studieswithout- comesr ecorded during hospitalization and foru pto3months followingsurgery.Mortality forpatients undergoing hip fracture surgery washigher,being 3.2%(95% CI 2.8 to3.6%) in twocohort studiesevaluating outcomesduring hospitalization. The pooled incidenceoffatalpulmonary embolismwas0.3%(95% CI 0to0.6%),therebycontributing about 10%towardsoverall mortality.Overall mortality and incidenceo ff atalp ulmonary embolismwashigheramong patients notreceiving prophylaxis.
Causeofdeath
Autopsy studies
Among patients undergoing electivejointreplacementonlyone studybySheppearde tal. wasidentifiedwherethe causesof deathweredetermined (13) . Inthisstudyof over3,000 patients (92%underwentautopsy),fatalp ulmonary embolismcontributed towards58% of deaths,withafurther10%o fd eaths caused byheart failure. Thecauseofdeath,asdeterminedbyobservationaland randomized trialshaving high autopsy rates (>60%),a mong patients undergoing hip fracturesurgery is shownintable 5. Pooled dataindicatethatvascularevents contributetowards3 2%o fall deaths,withsimilarproportionsof deathduetopulmonary embolism(10.5%),heart failure(9.8%), and myocardiali nfarction (8.6% events),ischemicheart diseaseaccounted for16%ofall deaths, followed byheart failure( 13%),pulmonary embolism( 10%), and stroke(7%).Overall mortality wasmaximalwithin thefirst 35days (6.8%),accounting for62%ofo verall mortality (11%) seen afterone year. Inthe Norwegianhip replacementstudies,involving 45,000 to65,000 patients undergoing electiveh ip replacementorhip fracturesurgery,three quarters of deathsw ered uetovascular causes(6,7),predominantlyw ithin the first 60 days.Thromboemboliccomplicationsaccounted for47%ofo verall mortality,followed bydeathsduetoischemicheart disease(40%) and stroke( 15%).The Oxfordrecordl inkage studys imilarlyr eviewed causesof deathamong over11,000 patients undergoing electivehip replacement (8) . Va scularevents accounted for59% of all deathswithin the first 90days,withthe majority of deaths duetoischemicheart disease(40%),followed bystrokeand pulmonary embolism.
Discussion
Datafromthisanalysisindicatethatpatients undergoing hip and knee replacementwho receiveprophylaxishaveanoverall mortality of 0.4 to0.6%within3monthsof surgery.Mortality in patients undergoing hip fracturesurgery iss ubstantiallyhigher, being 3to8.5% upto6monthsfollowingsurgery.Forbothelectiveand emergencyprocedures,overall mortality ishigher among thosepatients notreceiving prophylaxis.
Mortality followingelectivejointreplacementappearstobe maximalwithin thefirst 3months,thereafterthe mortality rate doesnotappeartoincreasebyone yearfollow-up,the exception being patients withadded comorbiditiessuchasrheumatoid arthritis (6, 8) . Mortality in patients undergoing hip fracturesurgery howevercontinuestoincreasewithtime,ranging from 5to 18% at3monthsfollow-up ( 5, (15) (16) (17) (18) (19) ,increasing tobe1 3t o 36%byone year (7, (20) (21) (22) (23) (24) (25) .
Furtherevidenceindicatesthattherehasbeenareduction in mortality followingelectivejointreplacementoverthe last decade. Information from the NationalHospitalDischarge Survey (26)and the United StatesBureauof the Census Compressed Mortality File (27),wereused toestimatetrendsin the mortality ratefrom hiporkneereplacementin the United Statesfrom 1979 through1998. Asignificantreduction in the all causemortality ratewasdemonstrated,being reduced from0.62 deathsper100 casesof hip orknee replacementin 1990to0.26 deathsper100 casesin 1998( P<0.0001) (P.Steinand R.Hull,personalcommunication).Reductionsin the population mortality ratef rom pulmonary embolismhavebeennoted overthe same timeperiod (28). Although exactr easonsfort hisdecreaseareunclear,improved surgicaland anesthesiologicaltechniquesand widespreaduseofprophylaxisarelikelytobecontributing factors.
Inour analysisof autopsy studies,vascularevents accounted forapproximatelyone thirdofall deathsfollowinghip fracture surgery.Withinclusion of datafrom the PEP study (5) ,the Norwegianh ip replacements tudies (6, 7) andthe Oxfordrecord linkage study (8) ,itisapparentthatvascularevents accountfor approximately50%o fall deaths,them ajority of whicho ccur within the first fewmonthsfollowingsurgery Inthisanalysis,the pooledfatalpulmonary embolismratefor patients undergoing electivehip orkneereplacementreceiving prophylaxiswas0.2to0.4%. Thisisin keeping withotherestimatesof fatalpulmonary embolisminpatients receiving in-hospitalp rophylaxis,b eing 0.1to0.4% following electiveh ip replacementand0.2to0.7%following knee replacement (9) . For patients undergoing hip fracturesurgery,the pooledrateforfatal pulmonary embolismf orpatients receiving prophylaxisw as 1.0%. Thishigherriskoffatalpulmonary embolismmayberelated toanumberof factors,includingthe preoperativenon-selection of patients,theage of the patientpopulation,multiple severeco-morbiditiesand alesserpre-operativecardio-respiratory and vascularreserve (20, 22, 29) .
Pooled datashowt hatpulmonary embolismcontributes toapproximately10to14% of all deathsfollowinghip fracture surgery withsimilarproportionsduetoo therfatalvascular events.Forpatients undergoing electiveprocedures,whereoverall mortality ratei smuchl owerduetothe predominantly selected and medicallyoptimizedpopulation,pulmonary embolismcontributest oasubstantiallyhigherproportion (85%) of deaths.Haake and Berkmann in theirreviewof autopsy studies showed similarfindings,fatalpulmonary embolismaccounting for6 7%f orall deathsin patients undergoing hip replacement and 38%ofall deathsin patients undergoing hip fracturesurgery (29) .
Thisanalysispredominantlypresents information concerning outcomesfollowingthe useofshort term(7to10days)prophylaxis.Mortality and the riskoffatalvascularevents arehoweverrecognizedtoremain elevated forseveralmonthsfollowing hospitald ischarge (6) .Studiesevaluating non-fatalo utcomes showasimilarprolonged period of risk,varying according tothe type of surgery performed. Venous thromboembolismfollowing knee replacementusuallyoccurs in the period immediatelyfollowingsurgery (9 to16days),whichextendsout toseveralweeks post surgery (27 to36 days)f ort hoseundergoing hip fracture surgery orhip replacement (30, 31) .
While clinicalattention isoftenf ocusedo np revention of mortality and fatalp ulmonary embolism,randomized clinical trialsevaluating prophylactictherapiespredominantlyreport the incidenceofobjectivelyconfirmedsubclinical(silent)deep-vein thrombosis.Thesesubclinicald eep-veinthrombiareusually treated withtherapeutica nticoagulation,therebyaltering the naturalh istory of thromboembolicevents and limiting anyassessmentof the potentialbenefits in preventing fataloutcomes. Inaddition,therolethatprophylactictherapymayplayin preventing arterialvascularevents followingmajororthopedicsurgery israrelyassessed in most trials.Futureevaluation of overall vascularmorbidity and mortality mayprovide additionali nformationconcerning the effectof antithrombotictherapieson reducing arterialandvenous events.
Our studyhasseveralpotentiallimitations.First,pooled data wered erived fromawidespectrumo frandomized controlled trialsand cohort studieswithdifferentdesignsand goals.Inan effort tominimizeuncertainty in eventrates,weattempted touse studiesin whichp atients underwentautopsyt od etermine the causeofdeathinconjunctionwithlarge cohort studiesthatwere methodologicallyr obust and reflectcurrents urgicalp ractice. Second,despiteanextensiveliteraturesearchforpublishedand unpublisheddata, apaucity of dataexists concerning the causes of fatalo utcomes,making itdifficultt op reciselyassess event rates.Manystudiesdid notreport clinicaloutcomesand ourfiguresmayindeed underestimatethe actualnumbersseen in clinicalpractice. Inparticular,in cohort studiespulmonary embolism isoftenclinicallymisdiagnosed and underestimated asacauseof deathduetoits clinicallyambiguous presentation,and assuch, deathcertificatesaren otoriouslyu nreliable (32, 33) .These studiesareopen label,often without centralblindedadjudication of events orsystematicclinicalfollowup. Third,the lengthoffollowu pvaried greatlydepending on the studiesconsidered. Therefore,alongerduration of follow-upwilll eadtoh igher numberof fataloutcomes.Fourthly,methodologicaldifferences arerecognizedi nanys tudiesevaluating the causeo fd eath. In observationalstudies,cardiac insufficiencyislikelytobeo verdiagnosedwhile fatalp ulmonary embolisme vents areunderdiagnosedd uetotheirs ilentnaturep riort od eath. Although autopsy studiesw ill eliminatem ucho fthisu ncertainty surrounding the causeo fd eathl imitationsexist in the mannerin whichtheyareperformed. Last,the lackofautopsy datain patients undergoing electiveh ip and knee replacementdidn ot allowusdrawanyfirmconclusionsconcerning the main causes of deathinthesepopulation groups.
Insummary,despitethromboprophylaxisbeing associated withareduction in overall mortality and fatalpulmonary embolism,vascularevents continuetobeac ommon causeo fd eath. Thei ncidenceo ff atalp ulmonary embolism( autopsy proven) among patients undergoing hip fracturesurgery remainsespeciallyhigh at1%.The findingsreaffirmprevious studyresults and demonstratethecontribution of vascularevents towardoverall mortality.Furtherprogress towardsreducing overall vascular mortality,especiallyamong hip fracturesurgery procedures, mayinvolvealternativemethodsorlongerdurationsof prophylaxis.
